The effect of Hydroxy citric acid on non alcoholic fatty liver disease

The effect of weight loss diet with and without Hydroxy citric Acid supplement derived from Garcinia Cambogia on the serum hepcidin level and liver function in women with NAFLD: A randomized controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503273320N11

Enrollment

Registered

2015-07-27

Start date

2015-08-01

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. fatty (change) of liver,not elsewhere classified

Interventions

Intervention 1: intervention group: weight loss diet plus 6 tablets (2 tablets 30 minutes before: breakfast- lunch - dinner) for 2 months. Intervention 2: control group: just get weight loss diet for

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: non-menopausal women with Non Alcoholic Fatty Liver Dieases 18-50 years BMI=27/5-40 kg/m2 moderate activity level

Exclusion criteria

Exclusion criteria: pregnancy or lactation alcohol consumption smoking anemia or thalassemia other metabolic disorders

Design outcomes

Secondary

Measure	Time frame
Anthropometry. Timepoint: at baseline and at the end of intervention. Method of measurement: scale,meter,bioelectrical impedance analyzer.;Energy and nutrients intake. Timepoint: at baseline and at the end of intervention. Method of measurement: 24- hour dietary recall.	—

Primary

Measure	Time frame
Serum level of hepcidin. Timepoint: at baseline,at the end of intervention. Method of measurement: ELIZA Kit.;Liver enzymes( ALT,AST,ALP). Timepoint: at baseline,at the end of intervention. Method of measurement: IFCC.;Liver steatosis. Timepoint: at baseline,at the end of intervention. Method of measurement: liver sonography.;Added at 2017-02-13: high sensivity-C Reactive Protein. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: immunoturbidometric.;Added at 2017-02-13: Fasting blood sugar. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: Radioimmunoassay.;Added at 2017-02-13: Fasting insulin. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: Radioimmunoassay.;Fasting ferritin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Glycated Hemoglobin. Timepoint: At the baseline and at the end of intervention. Method of measurement: High Performance Liquid Chromatography (HPLC).;Leptin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Adiponectin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Lipid profile ( HDL-C, TG,TC). Timepoint: At the baseline and at the end of intervention. Method of measurement: Enzymetic.;Interleukin-1 beta (IL-1ß). Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Interleukin- 6. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Tumor Necrosis Factor (TNF-a). Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.	—

Measure

Time frame

Serum level of hepcidin. Timepoint: at baseline,at the end of intervention. Method of measurement: ELIZA Kit.;Liver enzymes( ALT,AST,ALP). Timepoint: at baseline,at the end of intervention. Method of measurement: IFCC.;Liver steatosis. Timepoint: at baseline,at the end of intervention. Method of measurement: liver sonography.;Added at 2017-02-13: high sensivity-C Reactive Protein. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: immunoturbidometric.;Added at 2017-02-13: Fasting blood sugar. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: Radioimmunoassay.;Added at 2017-02-13: Fasting insulin. Timepoint: Added at 2017-02-13: At the baseline and at the end of intervention. Method of measurement: Added at 2017-02-13: Radioimmunoassay.;Fasting ferritin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Glycated Hemoglobin. Timepoint: At the baseline and at the end of intervention. Method of measurement: High Performance Liquid Chromatography (HPLC).;Leptin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Adiponectin. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Lipid profile ( HDL-C, TG,TC). Timepoint: At the baseline and at the end of intervention. Method of measurement: Enzymetic.;Interleukin-1 beta (IL-1ß). Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Interleukin- 6. Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.;Tumor Necrosis Factor (TNF-a). Timepoint: At the baseline and at the end of intervention. Method of measurement: ELIZA Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrangiz Ebrahimimamagani

Nutrition faculty,Tabriz university of medical science

ebrahimimamagani@tbzmed.ac.ir+98 41 3334 1113

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026